FEATURED COMPANIES
- 4D Pharma plc
- Ferring Pharmaceuticals
- Immuron Limited
- Naked Biome
- Quorum Innovations
- Sanofi S.A.
Key Questions Answered in this Report:
- What are the key features of human microbiome therapeutics which makes them a better choice for the treatment of chronic and non-communicable disease?
- What is the industry structure of the human microbiome therapeutics market?
- How did the human microbiome therapeutics market evolve and what is its scope in the future?
- What are the key development strategies which are implemented by the key players to maintain and capture market share?
- What are the major market drivers, challenges, and opportunities in the global human microbiome therapeutics market?
- What are the current leading companies dominating the global human microbiome therapeutics market?
- What are the regulations pertaining to the global human microbiome therapeutics market?
- What are the initiatives implemented by different government bodies to reduce the incidence of disease and increase the adoption of human microbiome therapeutics product?
- What was the market value of the leading segments and sub-segments of the global human microbiome therapeutics market?
- How is each segment of the global human microbiome therapeutics market expected to grow during the forecast period and what is the revenue expected to be generated by each of the segments by the end of 2029?
- Which region carries the potential for the significant expansion of key companies for human microbiome therapeutics market?
- Which products are anticipated to be launched and generate revenue in the forecast period 2019-2029?
Global Human Microbiome Therapeutics Market Forecast, 2019-2029
Human Microbiome Therapeutics Industry Analysis projects the market to grow at a significant CAGR of 33.00% during the forecast period 2019-2029. The human microbiome therapeutics market generated $309.9 million in revenue in 2018, in terms of value.
The human microbiome therapeutics growth has been primarily attributed to the major drivers in this market such as increasing prevalence and growing incidence of chronic diseases, growing investments and initiatives in the field of microbiome therapeutics, treatment options with minimal or no side effects, availability of private and government funding, and others. The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include product launches, and increasing mergers and acquisitions among the industry players. However, there are significant challenges that are restraining the market growth. These challenges include exorbitant cost is required for the clinical trials procedure and stringent regulatory guidelines for the product development and commercialization of the products.
Expert Quote
“With the elucidation of its causative role in cardiometabolic disease and atherosclerosis, the human gut microbiome holds promises as a reservoir of novel potential therapeutic targets as well as novel therapeutic agents, paving a new and exciting avenue in cardiovascular drug discovery and other areas.”
Scope of the Market Intelligence on Human Microbiome Therapeutics Market
The human microbiome therapeutics market research provides a holistic view of the global market in terms of various factors influencing it, including regulatory reforms, and technological advancements.
The scope of this report is centered upon conducting a detailed study of the products for different therapeutic applications in human microbiome therapeutics. In addition, the study also includes exhaustive information on expected commercial launches of the product in the forecast period, perception on the new product launches, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segments, and company, as well as other vital information with respect to global human microbiome therapeutics market.
Market Segmentation
The human microbiome therapeutics market is segmented into three categories, namely, product (by Phases), by disease, and by region.
The product segment includes the segmentation on the basis of different phases of clinical trials, and the disease segment includes, gastrointestinal and infectious diseases, oncology and autoimmune diseases, skin diseases, and neurological diseases.
The region segment is further segmented into North America, Europe, Asia-Pacific, and Rest-of-the-World.
Key Companies in the Global Human Microbiome Therapeutics Market
The key manufacturers who have been contributing significantly to the human microbiome therapeutics market include 4D Pharma plc, Immuron Limited, Sanofi SA., Seres Therapeutics Inc., Synthetic Biologics, Taisho Pharmaceutical, Ritter Pharmaceuticals, AOBiome, Finch Therapeutics, Rebiotix, Inc. (Subsidiary of Ferring Pharmaceutical), Maat Pharma, Ox Thera, Quorum Innovations, Vedanta Biosciences, Whole Biome, and Naked Biome among others.
FEATURED COMPANIES
- 4D Pharma plc
- Ferring Pharmaceuticals
- Immuron Limited
- Naked Biome
- Quorum Innovations
- Sanofi S.A.
Executive Summary
LOADING...
FEATURED COMPANIES
- 4D Pharma plc
- Ferring Pharmaceuticals
- Immuron Limited
- Naked Biome
- Quorum Innovations
- Sanofi S.A.
One of the undermined factors for the rising global disease burden is antimicrobial resistance (AMR). Mainly a natural phenomenon, antimicrobial resistance is triggered by the excess usage of antibiotics for the treatment of diseases with microbial origins. A complex issue of global concern, AMR is majorly driven by human action and perverse incentives. AMR is further accelerated by global trade and travel.
With AMR posing a significant burden on healthcare systems and national budgets worldwide, the world has now progressed into the ‘post-antibiotic era’. Common infections have again been rendered as fatal and are now demanding precise therapeutic modules. Thus, the governing bodies of different nations are restructuring their policies and norms in order to help the companies in reducing the cost and make advanced healthcare solutions which are accessible to a wide range of the population. The advent of precision medicine - a patient-centric treatment approach, is perceived to be promising in driving a paradigm shift in the healthcare industry, facilitating the elimination of uncertainty pertaining to trial and error method of medications, and consequently eliminating unnecessary healthcare spending. Thus, considerable acceptance has been received by the precision medicine approach in the healthcare industry.
The year 2003 marks the completion of the Human Genome Project, a 13-year, $3 billion collaborative effort for the sequencing and mapping of the complete human genome. This project further enabled scientists to research extensively on the gene variants to specific diseases and develop targeted therapeutics, depending on the genetic profile of an individual. The extension of the precision medicine approach through the Human Genome Project (HGP), the Human Microbiome Project (HMP) was implemented to acquire the ‘complete’ scope of the human body for precision care. The microbiota, constituting the entire population of the microbes residing within and on the human body, have been realized to be higher in population than the human cells – having an approximate ratio of 10:1, respectively. The microbiome, referred to as the genomic content of the microbiota, has now become an area of increasing focus to understand the function and role of the microbial components in disease incidence. NCDs, being an area direly in need of immediate therapeutic interventions, have naturally become a prevalent scope for human microbiome therapeutics.
According to this report, the global human microbiome therapeutics market was valued $309.9 million and is anticipated to grow at a CAGR of 33% in the forecast period 2019-2029.
- 4D Pharma plc
- AOBiome
- Finch Therapeutics
- Ferring Pharmaceuticals
- Immuron Limited
- MaaT Pharma
- Naked Biome
- OxThera AB
- Quorum Innovations
- Ritter Pharmaceuticals
- Sanofi S.A.
- Seres Therapeutics, Inc.
- Synthetic Biologics, Inc.
- Taisho Pharmaceutical
- Vedanta Biosciences, Inc.
- Whole Biome Inc.
